Your browser doesn't support javascript.
loading
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
Fendler, Annika; Au, Lewis; Shepherd, Scott T C; Byrne, Fiona; Cerrone, Maddalena; Boos, Laura Amanda; Rzeniewicz, Karolina; Gordon, William; Shum, Benjamin; Gerard, Camille L; Ward, Barry; Xie, Wenyi; Schmitt, Andreas M; Joharatnam-Hogan, Nalinie; Cornish, Georgina H; Pule, Martin; Mekkaoui, Leila; Ng, Kevin W; Carlyle, Eleanor; Edmonds, Kim; Rosario, Lyra Del; Sarker, Sarah; Lingard, Karla; Mangwende, Mary; Holt, Lucy; Ahmod, Hamid; Stone, Richard; Gomes, Camila; Flynn, Helen R; Agua-Doce, Ana; Hobson, Philip; Caidan, Simon; Howell, Michael; Wu, Mary; Goldstone, Robert; Crawford, Margaret; Cubitt, Laura; Patel, Harshil; Gavrielides, Mike; Nye, Emma; Snijders, Ambrosius P; MacRae, James I; Nicod, Jerome; Gronthoud, Firza; Shea, Robyn L; Messiou, Christina; Cunningham, David; Chau, Ian; Starling, Naureen; Turner, Nicholas.
Afiliación
  • Fendler A; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Au L; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Shepherd STC; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Byrne F; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Cerrone M; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Boos LA; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Rzeniewicz K; Tuberculosis Laboratory, The Francis Crick Institute, London, UK.
  • Gordon W; Department of Infectious Disease, Imperial College London, London, UK.
  • Shum B; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Gerard CL; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Ward B; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Xie W; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Schmitt AM; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Joharatnam-Hogan N; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Cornish GH; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Pule M; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Mekkaoui L; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Ng KW; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Carlyle E; Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK.
  • Edmonds K; Department of Haematology, University College London Cancer Institute, London, UK.
  • Rosario LD; Autolus Ltd., London, UK.
  • Sarker S; Autolus Ltd., London, UK.
  • Lingard K; Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK.
  • Mangwende M; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Holt L; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Ahmod H; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Stone R; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Gomes C; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Flynn HR; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Agua-Doce A; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Hobson P; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Caidan S; Experimental Histopathology Laboratory, The Francis Crick Institute, London, UK.
  • Howell M; Experimental Histopathology Laboratory, The Francis Crick Institute, London, UK.
  • Wu M; Mass Spectrometry Proteomics Science Technology Platform, The Francis Crick Institute, London, UK.
  • Goldstone R; Flow Cytometry Scientific Technology Platform, The Francis Crick Institute, London, UK.
  • Crawford M; Flow Cytometry Scientific Technology Platform, The Francis Crick Institute, London, UK.
  • Cubitt L; Safety, Health and Sustainability, The Francis Crick Institute, London, UK.
  • Patel H; High Throughput Screening Laboratory, The Francis Crick Institute, London, UK.
  • Gavrielides M; High Throughput Screening Laboratory, The Francis Crick Institute, London, UK.
  • Nye E; Advanced Sequencing Facility, The Francis Crick Institute, London, UK.
  • Snijders AP; Advanced Sequencing Facility, The Francis Crick Institute, London, UK.
  • MacRae JI; Advanced Sequencing Facility, The Francis Crick Institute, London, UK.
  • Nicod J; Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.
  • Gronthoud F; Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London, UK.
  • Shea RL; Experimental Histopathology Laboratory, The Francis Crick Institute, London, UK.
  • Messiou C; Mass Spectrometry Proteomics Science Technology Platform, The Francis Crick Institute, London, UK.
  • Cunningham D; Metabolomics Scientific Technology Platform, The Francis Crick Institute, London, UK.
  • Chau I; Advanced Sequencing Facility, The Francis Crick Institute, London, UK.
  • Starling N; Department of Pathology, The Royal Marsden NHS Foundation Trust, London, UK.
  • Turner N; Department of Pathology, The Royal Marsden NHS Foundation Trust, London, UK.
Nat Cancer ; 2(12): 1321-1337, 2021 12.
Article en En | MEDLINE | ID: mdl-35121900
ABSTRACT
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfocitos T / Anticuerpos Neutralizantes / COVID-19 / Anticuerpos Antivirales / Neoplasias Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Cancer Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfocitos T / Anticuerpos Neutralizantes / COVID-19 / Anticuerpos Antivirales / Neoplasias Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Cancer Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido